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Abstract
Background: The causes and mechanisms of late-onset neutropenia (LON) following rituximab treatment in
patients with rheumatic diseases are not known. In this study, we aimed to investigate the role of established
Fcγ receptor gene (FCGR) polymorphisms and B-cell-activating factor (BAFF) gene promoter polymorphisms for
the development of LON and for the efficacy of rituximab in patients with rheumatic diseases.
Methods: A single-center case-control retrospective study was nested in a cohort of 214 consecutive patients with
rheumatic diseases treated with rituximab. Eleven patients presented with LON. Fifty non-LON control subjects
were matched by diagnosis, age, sex, and treatments. Single-nucleotide polymorphisms of FCGR (FCGR2A 131H/R,
FCGR2B 232I/T, FCGR3A 158V/F) and BAFF promoter polymorphism −871C/T were analyzed with polymerase chain
reaction-based techniques, and serum immunoglobulin M (IgM) and BAFF levels were analyzed by enzyme-linked
immunosorbent assay. Flare-free survival was related to LON occurrence and polymorphisms.
Results: The FCGR3A V allele, but not other FCGR polymorphisms, correlated with the occurrence of LON; each V
allele conferred a fourfold increased OR for LON (p = 0.017). FCGR3A 158V/V and presentation with LON were
associated with a longer flare-free survival (p = 0.023 and p = 0.031, respectively). FCGR3A 158V/V was related to
lower IgM levels (p = 0.016). Serum BAFF levels showed no relationship with LON and BAFF −871C/T promoter
polymorphism. There was a tendency toward longer flare-free survival in patients with the BAFF −871T/T allotype
compared with the C/T or C/C allotypes (p = 0.096).
Conclusions: The results of the present study suggest that presentation with LON may be a result of the intrinsic
efficacy of rituximab in patients with rheumatic diseases. LON could indicate a longer biological and therapeutic
activity of rituximab modulated by a certain genotypic polymorphism: the high-affinity FCGR3A V allele. This
genotype and the occurrence of LON are both related to longer flare-free survival, suggestive of common
mechanisms for LON and duration of response to rituximab. The role of the BAFF −871C/T promoter polymorphism
in LON occurrence is unclear.
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Background
Late-onset neutropenia (LON) is now recognized as one
of the significant side effects of rituximab therapy that
may lead to serious infections. LON is defined as an ab-
solute blood neutrophil count <1.5 × 109/L occurring
4 weeks after the last rituximab infusion. The frequency
of LON in hematological malignancies and autoimmune
diseases is comparable. LON has been reported in 5–
27% of patients with lymphoma treated with rituximab
[1, 2] and in 1.5–23% of patients with rheumatic diseases
[3–6]. Because of the morbidity associated with LON, it
is important to understand the causes and mechanisms
of this phenomenon.
The binding of rituximab to Fcγ receptors (FcγRs) of
macrophages and natural killer (NK) cells is supposed to
influence therapeutic efficacy of rituximab [7]. A certain
single-nucleotide polymorphism (SNP) in the FCGR
gene, the FCGR3A 158V/V genotype (also called the
176V/V genotype), enhances ligation of rituximab to this
receptor [8, 9], and it has been associated with improved
clinical response in non-Hodgkin lymphoma and
rheumatoid arthritis (RA) [10–12], as well as with B-
lymphocyte depletion in patients with systemic lupus
erythematosus (SLE) [13]. The clinical relevance of other
FCGR genotypes is not known.
After depletion, B lymphocytes return to the peripheral
blood after a mean of 8 months [14]; this return is
preceded by increases in blood levels of B-cell-activating
factor (BAFF, also called B-lymphocyte stimulator or
BLyS). BAFF, a cytokine expressed mainly by neutrophils
and monocytes, plays a central role in the stimulation of
B-lymphocyte proliferation, differentiation, immunoglobu-
lin production, and survival [15]. Elevated serum BAFF
levels have been correlated to a poorer clinical outcome in
patients with rheumatic diseases [16, 17]. Thus, regula-
tion of BAFF expression may affect the efficacy of ri-
tuximab. Enhanced generation of BAFF has been
associated with the presence of a certain SNP of the
BAFF gene promoter (the −871C/T genotype) [18–20].
Recently, the BAFF −871C/T promoter polymorphism
has been reported to influence the response to rituxi-
mab in patients with RA [20, 21].
Predisposing factors for LON and the potential clinical
consequences of LON are poorly defined. We therefore
conducted a nested case-control analysis of a cohort of
rituximab-treated patients with rheumatic diseases. We
hypothesized that three established FCGR polymor-
phisms—FCGR2A 131H/R, FCGR2B 232I/T, and FCGR3A
158V/F—and the BAFF −871C/T promoter polymorphism
are related to occurrence of LON through modified thera-
peutic activity of rituximab. We thus investigated the pos-
sible predictive role of the polymorphisms for LON.
Second, in this study with an extended initial control popu-
lation [3], we examined the relationship between LON and
serum levels of immunoglobulin M (IgM) and also BAFF
levels. Finally, we asked whether the efficacy of rituximab
differs between patients with LON and those without LON.
Methods
Study design and patients
All 214 consecutive adult patients treated with rituximab
for rheumatic diseases from June 2003 until March 2009
and followed for at least 12 months at the Department of
Rheumatology, Karolinska University Hospital Huddinge,
Stockholm, Sweden, qualified for inclusion in the study.
The medical records were retrospectively reviewed until
December 2011 and also 2 years prior to initiation of ri-
tuximab. Five cases in which neutropenia could have de-
veloped as a consequence of the autoimmune disorder per
se or prior therapy were excluded. (For details, see [3].)
Overall, 11 cases of LON were identified at routine
follow-up or emergency visits, as previously reported [3].
LON occurred after the first rituximab treatment in seven
cases and after the second in four cases. The control sub-
jects (50 non-LON patients) were drawn from the whole
study population after the diagnoses and were representa-
tive of and proportional to the LON cases (i.e., SLE, anti-
neutrophil cytoplasmic antibody-associated vasculitis
[AAV] and RA) with available blood samples. The control
patients were matched by age, sex, and previous and con-
current treatments to the patients with LON (Fig. 1 and
Table 1). The diagnoses of SLE, AAV, and RA satisfied
Fig. 1 Chart of the selection of the study population. LON Late-onset
neutropenia
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American College of Rheumatology classification criteria
[22–24].
Rituximab therapy
Details of the therapies and patient selection are
given in Table 1 and Fig. 1. Briefly, all patients re-
ceived rituximab because of the inefficacy of other
immunosuppressives or contraindications for stand-
ard therapies. Initiation and dosing of rituximab
were based on the discretion of the treating phys-
ician. A rituximab infusion of 375 mg/m2 weekly for
4 weeks was offered for patients with SLE and pa-
tients with AAV, and two doses of 1 g or 0.5 g were
given to patients with RA. Steroid and immunosup-
pressive regimens were sequentially reduced as clin-
ically needed.
Patients were assessed according to a standard care
protocol, which included history taking, a physical exam-
ination, and laboratory tests at the decision to treat or be-
fore first administration of rituximab. Assessments were
repeated each 3–6 months during follow-up, with add-
itional visits scheduled as clinically needed. For patients
who experienced flares, standard therapy was initiated,
such as retreatment with rituximab or other biologics,
disease-modifying antirheumatic drugs (DMARDs), and/
or glucocorticoids. Retreatment with rituximab because of
Table 1 Characteristics of 61 patients, by group according to occurrence of late-onset neutropenia during follow-up
Total (n = 61) LON (n = 11) Non-LON
(n = 50)
P value
Age at rituximab start, years, mean (SD), range 57.3 (16.4), 18–85 58.9 (18.2), 29–82 57.0 (16.2), 18–85 0.73
Female sex, % 75.4 72.7 76.0 0.82
Disease characteristics
Diagnosis 0.82
SLE, % 23.0 27.3 22.0
AAV, % 21.3 27.3 20.0
RA-seropositive, % 37.7 36.4 38.0
RA-seronegative, % 18.0 9.1 20.0
Disease duration, years, median (IQR) 7.0 (3.0–13.0) 4.0 (2.0–11.0) 7.5 (3.0–13.3) 0.43
Previous treatments
Number of DMARDs, mean (SD), range 3.6 (1.8), 0–8 4.1 (2.1), 1–8 3.5 (1.8), 0–7 0.27
Cytotoxics and biologics, % 63.9 81.8 60.0 0.30
Prednisolone, % 98.4 100 98.0 1.0
Major indication for rituximab, by manifestations 0.15
Arthritis and dermatologic, % 59.0 45.5 62.0
Renal, % 19.7 9.1 22.2
Pulmonary and ENT, % 16.4 27.3 14.0
Neurologic, % 3.3 9.1 2.0
Hematologic, % 1.6 9.1 0
Rituximab regimens 0.84
375 mg/m2 weekly for 4 weeks, % 14.8 9.1 16.0
1 g twice 2 weeks apart, % 59.0 63.6 58.0
0.5 g twice 2 weeks apart, % 26.2 27.3 26.0
Concurrent DMARDs
Any DMARDs, % 78.7 72.7 80.0 0.69
Cyclophosphamide, % 21.3 27.3 20.0
Azathioprine, % 9.8 9.1 10.0
Mycophenolate mofetil, % 8.2 9.1 8.0
Methotrexate, % 34.4 9.1 40.0
Concurrent prednisolone, % 88.5 100 86.0 0.33
The p values refer to the comparisons between LON and non-LON groups. Cytotoxics used were cyclophosphamide and chlorambucil
Abbreviations: LON Late-onset neutropenia, SLE Systemic lupus erythematosus; AAV Antineutrophil cytoplasmic antibody-associated vasculitis, RA Rheumatoid
arthritis, DMARDs Disease-modifying antirheumatic drugs, ENT Ear, nose, throat
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flare was never initiated before 12 months from the previ-
ous rituximab treatment cycle. Blood samples for biobank-
ing were collected at baseline and 3, 6, and 12 months of
follow-up.
Time to flare
Time to flare was defined as the time from the day of ri-
tuximab initiation to the time of recurrence or new
symptoms that warranted therapy escalation beyond a
temporary increase in the glucocorticoid dosage. For the
purpose of rituximab response analysis, follow-up after a
rituximab cycle leading to neutropenia was censored at
the time of flare or retreatment with rituximab or other
agents; otherwise, follow-up was ended at the time of
the last evaluation in December 2011.
Laboratory tests
Genotyping was performed in all 61 patients. Genomic
DNA was isolated from peripheral blood mononuclear
cells using QIAamp® DNA Blood Mini Kit according to
the recommendations of the manufacturer (Qiagen,
Hilden, Germany). FCGR genotyping of the SNPs 158V/
F (rs396991) in the FCGR3A gene and 131H/R
(rs1801274) in the FCGR2A gene was performed with
allelic discrimination using two TaqMan assays (C_
9077561_10 and C_25815666_20, respectively; Applied
Biosystems, Foster City, CA, USA) with supplied probes
and primers on a Rotor-Gene 6000 real-time system
(Qiagen). FCGR2B 232I/T (rs1050501) genotyping was
performed using oligonucleotide probing based on
fluorescence resonance energy transfer technology as
previously described [25]. BAFF −871C/T (rs9514828)
genotyping was performed by restriction fragment length
polymorphism analysis. The primers used for BAFF pro-
moter amplification were 5′-GGCACAGTCAACATGG-
GAGT-3′ (forward) and 5′-GCTAAGTGTTTTAGCAT
TGAATTG-3′ (reverse) as previously described [26].
The polymerase chain reaction products were subjected
to a restriction enzyme-based screening of −871C/T
using 20 U of BsrBI restriction enzyme. All genotyping
results were in consistent with Hardy-Weinberg equilib-
rium, and genotyping efficiency was validated (Haplo-
view v.4.1 software; Broad Institute, Cambridge, MA,
USA). All samples were run in duplicates-triplicates.
Serum levels of human BAFF were determined by
using the Quantikine BAFF enzyme-linked immunosorb-
ent assay (R&D Systems, Abingdon, UK) according to
the recommendations of the manufacturer. Serum im-
munoglobulin levels were assessed according to standard
clinical procedures.
Statistical methods
The chi-square and two-sided Fisher’s exact tests
were used for comparisons as suitable. The Wilcoxon
matched pairs signed-rank test was used to analyze
within-group changes at follow-up. The relationship
between gene polymorphisms and LON occurrence
was analyzed by Spearman’s correlation analysis and
logistic regression. Analyses of serum IgM levels over
time were done with linear mixed models. The
Kaplan-Meier method with the log-rank test was ap-
plied to determine the difference between flare-free
survival 12 months following rituximab in the LON
and non-LON groups. The duration of follow-up for
the survival analyses was chosen on the basis of mean
period of rituximab-induced B-lymphocyte depletion
in patients with rheumatic disease [14].
Results
The studied population comprised 61 patients, 11 of
whom experienced LON during follow-up and 50
matched control patients who did not (non-LON)
(Table 1). Demographic and disease characteristics did
not differ between the groups (Table 1). At the initiation
of rituximab therapy, patients were a mean (SD) of 57.3
(16.4) years old and had a median disease duration of
7 years. In addition to rituximab, all patients were given
immunotherapy with DMARDs and/or prednisolone.
The patients were followed for at least 12 months and
up to 5.6 years after rituximab therapy.
Genotype distributions in patients with LON and control
subjects without LON
The distribution of genotypes differed significantly be-
tween LON and non-LON groups (Fig. 2).
Among patients who developed LON, 55% were
homozygous for the high-affinity V allele of the FCGR3A
gene, as compared with 27% of non-LON patients (p =
0.086). The number of V alleles was significantly corre-
lated to LON (r = 0.42, p = 0.01). Next, we examined
how much each V allele affected the risk for LON devel-
opment. We found that each additional V allele was as-
sociated with a fourfold increased risk of LON (OR 4.0,
95% CI 1.0–16.7, p = 0.017).
Even if the number of cases was limited, no statistically
significant associations were found between LON and the
FCGR2A 131H/R or FCGR2B 232I/T genotype. Of note,
there was a contrasting relationship in the distribution of
the FCGR2B and the FCGR3A genotypes in the LON and
non-LON groups (Fig. 2). Thus, the high-affinity FCGR3A
158V/V allotype was more frequent, whereas the low-
affinity FCGR2B 232I/I allotype was less frequent, in the
LON group than in the non-LON group. The same pat-
tern also yielded the distributions of V/F versus I/T and F/
F versus T/T between the groups. The BAFF −871T/T
genotype, which is associated with higher BAFF levels [14,
15], was more frequent in the LON group than in the
non-LON group (45% vs. 24%; p = 0.12) (Fig. 2).
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Serum BAFF levels and BAFF promoter polymorphism
After rituximab treatment, there was an increase of
serum BAFF levels at 3 months and a decrease there-
after. There was no statistically significant difference in
serum BAFF levels at baseline and after 3 and 6 months,
or for changes from baseline to follow-up, between the
LON and non-LON groups (Fig. 3). We then analyzed
the relationship between the BAFF −871T/T genotype and
serum BAFF levels. In both the LON and the non-LON
groups, we observed a trendwise positive association
between possession of the T allele (compared with the C
allele) and an increase in serum BAFF levels from 0 to
3 months (r = 0.27, p = 0.073).
Serum immunoglobulin levels in relation to LON and FcγR
and BAFF polymorphisms
We previously showed that patients with rheumatic
diseases who developed LON after rituximab treatment
had lower serum IgM levels for a longer period than
matched non-LON control subjects [19]. In the present
Fig. 2 Distribution of FCGR and BAFF promoter gene polymorphisms in the patients who developed late-onset neutropenia (LON) during follow-up
and the matched control patients who did not (non-LON). BAFF B-cell-activating factor
Fig. 3 Box plots (median, minimum, and maximum) of serum B-cell-activating factor (BAFF) and immunoglobulin M (IgM) levels after rituximab
treatment during follow-up by late-onset neutropenia (LON) occurrence. Diagonal lined boxes represent the LON group, and open boxes represent
the non-LON group. The numbers of patients with available serum for measurement of serum BAFF levels in the LON group were 11 at treatment
initiation, 7 at 3 months, and 4 at 6 and 12 months; in the non-LON group, the respective numbers of patients with BAFF measurements were
48, 39, 24, and 5. The numbers of patients with measured IgM serum levels in the LON group were 11 at baseline, 10 at 6 months, and 8 at
12 months; the respective numbers of patients in the non-LON group were 47, 42, and 22
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study, the non-LON control group was extended. Base-
line IgM levels were similar in the LON and non-
LON groups. However, compared with the non-LON
control subjects, patients with LON had a more pro-
nounced decrease in IgM levels from baseline to the
lowest values in the first year after rituximab treat-
ment (median (IQR)−0.37 [-0.25 to- 0.60] g/L vs. −0.2
[-0.01 to - 0.50] g/L, p = 0.042). The previous obser-
vation of lower serum IgM during follow-up in the
patients who developed LON was hence confirmed.
Because enhanced binding of rituximab to FcγRs
might confer more pronounced and/or prolonged IgM
reduction, and because recovery of immunoglobulin
production is partly governed by BAFF [13], we next
examined whether changes in serum IgM levels were
related to FCGR and BAFF genotypes. There was no
significant difference in IgM levels in the FCGR3A
158V/V, V/F, and F/F groups at baseline. However, pa-
tients homozygous for the high-affinity V allele of
FCGR3A had lower IgM levels over time than those
with the low-affinity F allele, independently of sex
and previous treatments (β = −0.30, 95% CI −0.54 to
−0.06; p = 0.016). We found no significant association
between IgM levels and other tested FCGR and BAFF
promoter polymorphisms. No association was found
between serum immunoglobulin G (IgG) levels at
baseline or over time with LON occurrence or the
genetic polymorphisms.
Time to flare in relation to LON and FCGR and BAFF
polymorphisms
Because of the higher affinity of the Fc portion of anti-
CD20 monoclonal antibodies on FcγRs, more efficient
binding and activation of NK cells are rationales for both
the occurrence of neutropenia in the context of rituximab
and the clinical response to rituximab. Therefore, we
asked if LON is associated with clinical benefit as a longer
time to flare. Because B-lymphocyte depletion and clinical
effect following rituximab commonly lasts <12 months
[14], evaluation was done at 12-month follow-up visits.
Of all patients, 87% experienced flares during 5 years
of follow-up; the proportions were 86% in the LON
group and 91% in the non-LON group (Fig. 4a). The me-
dian times to flare were 12 (8.0–19.5) months in the
LON group and 7.5 (6–13) months in the non-LON
control group (p = 0.22). There were fewer patients in
the LON group who experienced flares within 12 months
(36.4%) than in the control group (60.0%) (p = 0.15).
At the 12-month assessment, LON occurrence was
positively correlated to time to flare (r = 0.27, p = 0.043).
The presence of LON was associated with lower odds of
flare (OR 0.10, 95% CI 0.01–0.92; p = 0.028). Figure 4b
presents the Kaplan-Meier estimates of the percentages
of patients with flare-free follow-up in the LON and
non-LON groups. Patients who developed neutropenia
had a longer flare-free survival than the control subjects
without it (p = 0.031).
Fig. 4 Kaplan-Meier estimates of the percentages of patients without flare from the time of rituximab therapy in total and by groups of late-onset
neutropenia (LON) occurrence and genotypic polymorphism. Depicted are flare-free survival estimates for 61 patients after treatment with
rituximab through the observation period (53 flares) (a) and during the 12-month follow-up (34 flares) in the groups by occurrence of LON (b), by
FCGR3A 158V/F polymorphism (c), and by B-cell-activating factor (BAFF) −871C/T polymorphism (d)
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Considering the relationship between the FCGR3A
158V/V genotype and the occurrence of LON shown in
our analysis, we found, as expected, a significant positive
correlation between this allotype (vs. V/F or F/F) and
time to flare (r = 0.29, p = 0.039). Possession of the V
allele was negatively associated with flare at 12-month
assessment (OR 0.10, 95% CI, 0.03–0.42, p = 0.034). The
Kaplan-Meier curves illustrate the difference in flare-free
survival by possession of the FCGR3A 158V/V polymorph-
ism (p = 0.023) (Fig. 4c). No association between other
tested FCGR polymorphisms and flare-free survival was
found, whereas patients with the BAFF −871T/T allotype
tended to have a longer flare-free survival than those with
the BAFF −871C/T or C/C allotype (p = 0.096) (Fig. 4d).
Discussion
In this prospective case-control analysis nested within a
large cohort of rituximab-treated patients with rheum-
atic diseases, we examined possible genetic bases for the
occurrence of LON and the consequences of presenta-
tion with that complication in the largest dataset of re-
ported LON cases reported to date. We showed, for the
first time to our knowledge, the relationship between the
occurrence of LON and possession of the high-affinity
FCGR3A V allele. We also confirmed a previous observa-
tion of lower serum IgM levels in patients with LON
than in those who did not develop LON. Further, an as-
sociation between the FCGR3A V allele and lower serum
IgM levels was demonstrated. Finally, we observed a fa-
vorable association between both LON and the FCGR3A
V allele and a longer duration of flare-free survival
following rituximab therapy. Taken together, these find-
ings suggest that the variation in quality of clinical re-
sponse to rituximab may be explained by genotypic
polymorphism in a certain FcγR, and that a more pro-
nounced B-cell depletion could likely account for both
occurrence of LON and longer therapeutic activity of
rituximab. Although patients with the BAFF −871T/T al-
lotype had a longer flare-free survival than patients with
the BAFF −871C/T or C/C allotype, no significance of
serum BAFF levels related to LON occurrence was
found.
LON represents a potentially severe clinical phenomenon
occurring after rituximab treatment in patients with lymph-
oma and patients with rheumatic disease. At the time of
LON occurrence, up to a 90% infection rate is reported in
patients with rheumatic disease diagnoses, and in many
patients granulocyte colony-stimulating factor (G-CSF) is
required [3, 11]. It is therefore of clinical importance to de-
fine predisposing factors for LON. To some extent, this has
been investigated in patients with lymphoma. Thus, high
cumulative doses of myelotoxic agents, including autolo-
gous stem cell transplant, have been proposed as a predict-
ive factor for LON [27–29].
The biological rationale to investigate FCGR polymor-
phisms is based on the hypothesis that LON is related to
higher binding of the Fc part of rituximab to the FcγR
on macrophages and NK cells, conferring an increased
efficacy of the antibody-dependent cellular cytotoxicity
(ADCC) process that leads to depletion of B lympho-
cytes. The FcγRIIIa and FcγRIIa receptors, which mainly
mediate proinflammatory activity, as well as the FcγRIIb
receptor with anti-inflammatory activity, may be of
significance for the ADCC process [30]. FCGR3A V
allotype is the most thoroughly investigated and is known
to display higher affinity for IgG1 antibody (such as rituxi-
mab) than the FCGR3A F allotype. Patients carrying the
V/V genotype, compared with the V/F and F/F genotypes,
demonstrate higher biological and clinical responses to ri-
tuximab in the treatment of B-lymphoproliferative malig-
nancies, RA and SLE [9, 13, 31].
In addition to SNPs in the FCGR gene, the role of
copy number variation has been proposed to be related
to the efficacy of antibody-based drugs [32] and differen-
tial susceptibility to autoimmune diseases [33]. FCGR
gene copy number variation was not assessed in our
sample. Investigation of whether the FCGR gene copy
number genotypic profile is associated with occurrence
of LON requires larger study populations.
To the best of our knowledge, this report is the first re-
garding the relationship between LON occurrence and
possession of the high-affinity FCGR3AV allele in patients
with rheumatic disease. This finding is in line with a re-
port on patients with lymphoma in which the FCGR3A
158V/F polymorphism was suggested as a novel risk factor
for LON [34, 35]. We also extended our analysis to several
FcγR types. In this context, the role of possession of the
anti-inflammatory FcγRIIb was of particular interest, not
only because of its largely opposing effects compared with
FcγRIIIa in mediating actions of antibodies but also be-
cause it is expressed mainly on B lymphocytes [30, 36].
The significance of polymorphisms in the FCGR2A and
FCGR2B genes for LON occurrence was not documented
here, however. We acknowledge that our analysis had lim-
ited statistical power to estimate the contribution of the
FCGR2B 232I/I polymorphism; taking into account its
prevalence in the LON and non-LON groups, a sample
size of 96 patients in each group would have been re-
quired to detect a difference with 80% statistical power
(based on the normal approximation to the binomial dis-
tribution). Considering the low numbers of patients in our
study, the negative findings do not exclude a role of other
polymorphisms and FcγRs for developing LON. Of note,
we observed differences in the distribution of FCGR poly-
morphisms in the LON and non-LON groups, with more
frequent FCGR2A 131H/H and FCGR2B 232I/I polymor-
phisms among patients who developed LON than among
control subjects.
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Previously, we reported that occurrence of LON is
associated with a more pronounced and sustained B-
lymphocyte depletion and lower levels of serum IgM fol-
lowing rituximab than in matched control subjects with
a similar history of previous antirheumatic therapy [3].
In the present study with an extended control group of
patients who did not develop LON following rituximab
therapy, the presence of lower serum IgM levels in the
LON group than in non-LON control subjects was con-
firmed. In the present study, we further found that the
homozygosis for the high-affinity V allele of FCGR3A
was correlated to lower IgM levels over time compared
with the low-affinity F allele.
These findings suggest that the high-affinity V allele of
FCGR3A, leading to an enhanced binding of rituximab
to FcγRs, might confer deeper and more prolonged B-
lymphocyte depletion that may result in both LON and
more pronounced and prolonged decrease of serum
IgM. Whether monitoring of serum IgM levels in pa-
tients with a certain genotypic polymorphism may be
useful for prediction of LON development is to be ad-
dressed in larger prospective studies.
In this study, we found no significant association
between LON and serum BAFF levels or BAFF promoter
polymorphisms (which may influence serum BAFF
levels), but the number of available blood samples was
limited, and only a few samples were drawn during the
LON period. Patients with the BAFF −871T/T allotype,
however, had a better clinical response with a longer
flare-free survival than patients with the BAFF −871C/T
or C/C allotype. Though caution is needed in interpret-
ation of the findings of our analysis in patients with
different rheumatic diseases, our findings are in line with
a reported improved response to rituximab in patients
with seropositive RA carrying the BAFF −871T/T
allotype [20]. To avoid findings by chance, we did not
proceed with a subanalysis in patients possessing
autoantibodies. Further study of BAFF regulation in the
context of severe acute neutropenia is of particular inter-
est because BAFF is produced largely by neutrophils and
monocytes and because BAFF expression is augmented
by G-CSF [37], which is often used for patients who
present with infectious complications due to LON.
The present analysis demonstrated that the occurrence
of LON and the FCGR3A 158V/V genotype both were re-
lated to a longer time to flare of the rheumatic diseases.
Transient neutropenia is recognized in idiosyncratic drug-
induced neutropenia and agranulocytosis [38]. Our find-
ings of lower serum IgM levels in patients who developed
LON and lower serum IgM levels in association with the
FCGR3AV allele, together with a longer time to flare, indi-
cate that the phenomenon of LON is of a different nature
than drug-induced agranulocytosis and that LON is likely
explained by biological mechanisms of rituximab action
modified through FCGR genotypes (i.e., a more pro-
nounced B-cell depletion).
Although we report a potentially important finding,
LON is a rare clinical phenotype, and there were only 11
cases of LON associated with rituximab in our study.
Our results should be verified in larger cohorts per-
formed in disease-specific patient populations with a lar-
ger number of cases presenting with LON. Statistical
power to evaluate the effect of genetic variation on a
rare event such as LON could be improved by perform-
ing meta-analyses of combined data from several co-
horts. The small number of cases in the present study
probably limited the chance of detection of effects of
some genotypic polymorphisms (type II error), but the
main results appear to be in line with those in previous
reports. The strength of the study lies in its advantage of
a large cohort of 214 consecutive patients treated with
rituximab who were followed prospectively with a variety
of important clinical and laboratory data. The possible
confounding effects of exposure to other significant
drugs was minimized (as could not formally be over-
come in the observational study) by individual matching
of the LON cases and control cases by the cumulative
number of previously used DMARDs; use of cytotoxic
and biologic therapies; and concurrent treatment with
DMARDs, cyclophosphamide, and corticosteroids. The
patients represented a typical, clinic-based, “real-life”
patient population treated with rituximab; thus, the
selection bias was minimal because our center provides
care for patients with the whole spectrum of rheumatic
diseases.
Conclusions
A novel association between the occurrence of LON and
the possession of a SNP in the FCGR3A gene adds to the
understanding of the LON phenomenon in patients with
rheumatic disease treated with rituximab. Our results sug-
gest that LON is a result of the intrinsic efficacy of rituxi-
mab. The presentation with LON may indicate a longer
biological and therapeutic activity of rituximab modulated
by certain genotypic polymorphisms. Our findings suggest
that the prognosis of therapeutic efficacy and risk for a po-
tentially severe adverse reaction following rituximab ther-
apy may benefit from including genotypic characterization.
The findings of the study fuel the need for further compre-
hensive mechanistic studies on therapeutic activity of ritux-
imab and other antibody agents.
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